Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

June 12, 2019

Study Completion Date

June 12, 2019

Conditions
Psoriasis
Interventions
DRUG

MP1032

hard gelatin capsules containing 50mg MP1032 as active ingredient

DRUG

Placebo

hard gelatin capsules containing no active ingredient

Trial Locations (19)

Unknown

Dr. Tsianakas / Dr. Ameluxen, Bad Bentheim

Rothaar Studien GmbH, Berlin

Dr. Johannes Niesmann / Dr. Othlinghaus, Bochum

Klinische Forschung Dresden GmbH, Dresden

MensingDerma, Hamburg

MVZ DermaKiel, Kiel

Hautarztpraxis Dres. med. Scholz, Sebastian, Schilling, Mahlow

Universitätsmedizin Mainz, Hautklinik und Poliklinik, Mainz

Klinische Forschung Schwerin (kfsn), Schwerin

Centroderm GmbH, Wuppertal

GynCentrum Sp. Z o.o., Katowice

MULTIKLINIKA SALUTE Sp. z o. o., Katowice

Provita Sp. z o.o., Centrum Medyczne Angelius Provita, Katowice

CENTRUM MEDYCZNE PLEJADY Sp. z o. o. spółka komandytowa, Krakow

Dermoklinika Centrum Medyczne s.c. M.Kierstan, J.Narbutt, A.Lesiak, Lodz

Dermedic Jacek Zdybski, Ostrowiec Świętokrzyski

Kliniczny Szpital Wojewódzki nr 1 im. Fryderyka Chopina w Rzeszowie, Klinika Dermatologii, Rzeszów

Laser Clinic s.c. Andrzej Królicki, Tomasz Kochanowski, Szczecin

DermMEDICA Sp. z o.o., Wroclaw

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bioskin GmbH

INDUSTRY

lead

MetrioPharm AG

INDUSTRY

NCT03706209 - Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter